Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) is a clinical-stage gene editing company focused on developing in vivo therapies for genetic and infectious diseases using its proprietary ARCUS platform. This Form 10-Q covers the quarterly period ended March 31, 2025. The company operates as a single segment and is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $29,000 | $17,584,000 |
| Net Loss | $(20,565,000) | $8,588,000 (Income) |
| Operating Loss | $(22,112,000) | $(4,187,000) |
| Net Cash Used in Operating Activities | $(19,052,000) | $(18,981,000) |
| Cash, Cash Equivalents, and Restricted Cash | $99,789,000 | $137,766,000 |
| Total Debt (Loan Payable) | $22,337,000 | $22,321,000 |
| Accumulated Deficit | $(503,029,000) | $(482,464,000) |
Per Share Data: Basic and diluted net loss per share was $(2.21) for Q1 2025, compared to net income per share of $1.70 in Q1 2024.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped 99.8% to $29,000 from $17.6 million in Q1 2024. This decrease is primarily due to the recognition of $8.5 million in revenue from the TG Therapeutics license agreement and $4.5 million from the Prevail Therapeutics agreement in the prior year, neither of which generated revenue in Q1 2025. Additionally, revenue from the Novartis agreement decreased by $4.5 million as the company nears the completion of its pre-clinical workplan.
- Operating Expenses: Total operating expenses increased slightly by $370,000 to $22.1 million. Research and Development (R&D) expenses rose by $245,000, driven by increased external development costs for the PBGENE-DMD ($2.3M increase) and PBGENE-3243 ($1.0M increase) programs, partially offset by a $1.5M decrease in PBGENE-HBV costs as it transitions to clinical trials.
- Other Income/Expense: The company reported a net loss of $20.6 million compared to net income of $8.6 million in the prior year. This swing was significantly influenced by a $11.2 million decrease in "Other income," largely due to a $10.4 million gain on the change in fair value of warrant liability in Q1 2024 versus a $0.8 million loss in Q1 2025.
- Liquidity: Cash and cash equivalents decreased by $8.7 million during the quarter, primarily due to operating cash outflows of $19.1 million, partially offset by $10.7 million in financing activities (primarily ATM offerings).
Guidance, Outlook, and Risks
- Program Updates:
- PBGENE-HBV: Received FDA Fast Track designation in April 2025. Initial safety data from Cohort 1 showed the treatment was safe and well-tolerated, with substantial reduction in Hepatitis B surface antigen in two of three participants.
- PBGENE-DMD: Preclinical data presented in May 2025 demonstrated significant functional improvement in a humanized mouse model. The company plans to file an IND/CTA in 2025 with clinical data expected in 2026.
- PBGENE-3243: Development will be paused to prioritize PBGENE-HBV and PBGENE-DMD, with future development staged after Phase 1 results for the other programs.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and expected operational receipts (including potential near-term consideration from licensees) will fund operations into the second half of 2026. This runway is expected to support first-in-human Phase 1 clinical data for two wholly-owned programs.
- Capital Constraints: The company is subject to the "Baby Shelf Rule," limiting the amount of proceeds it can raise via its Form S-3 shelf registration (including ATM offerings) to one-third of its public float until the float exceeds $75 million.
- Key Risks:
- Significant operating losses and an accumulated deficit of $503 million.
- Dependence on the success of the novel ARCUS technology and the ability to raise additional capital.
- Regulatory uncertainties regarding genome editing and clinical trial outcomes.
- Competition from other genome editing technologies (e.g., CRISPR/Cas9).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $99.8 million cash balance to fund operations through the second half of 2026, considering the "Baby Shelf Rule" limitations on raising additional capital.
- Revenue Recognition: Confirm the timing of future milestone payments from the TG Therapeutics agreement (specifically the $7.5 million initial milestone) and the Novartis agreement.
- Clinical Progress: Monitor the enrollment and safety data for the PBGENE-HBV ELIMINATE-B trial and the IND filing timeline for PBGENE-DMD.
- Debt Covenants: Review the terms of the $22.5 million term loan with Banc of California, specifically the requirement to maintain a cash security account equal to the outstanding principal.
- Warrant Liability: Assess the volatility impact of the $3.6 million warrant liability on future earnings, as fair value adjustments are recorded in the income statement.